Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Laura S GrahamLawrence D TrueRoman GulatiGeorge R SchadeJonathan WrightPetros GrivasTodd YezefskiKatie NegaKaterina AlexanderWen-Min HouEvan Y YuBruce MontgomeryElahe A MostaghelAlvin A MatsumotoBrett MarckNima SharifiWilliam J EllisNicholas P RederDaniel W LinPeter S NelsonMichael T SchweizerPublished in: The Prostate (2021)
In men with high-risk PC, pCR rates remained low even with combinatorial AR-directed therapy, although rates of MRD were higher. Ongoing follow-up is needed to validate clinical outcomes of men who achieve MRD.